Your browser is no longer supported. Please, upgrade your browser.
Settings
FGEN FibroGen, Inc. daily Stock Chart
FGEN [NASD]
FibroGen, Inc.
Index- P/E- EPS (ttm)-1.92 Insider Own5.50% Shs Outstand70.25M Perf Week-1.56%
Market Cap2.88B Forward P/E- EPS next Y-0.45 Insider Trans-15.61% Shs Float60.28M Perf Month16.31%
Income-124.50M PEG- EPS next Q-0.36 Inst Own47.00% Short Float3.06% Perf Quarter53.27%
Sales117.90M P/S24.43 EPS this Y30.90% Inst Trans3.61% Short Ratio2.56 Perf Half Y66.67%
Book/sh3.30 P/B12.42 EPS next Y75.30% ROA-25.70% Target Price69.40 Perf Year122.34%
Cash/sh5.12 P/C8.01 EPS next 5Y- ROE-71.60% 52W Range15.60 - 51.70 Perf YTD91.59%
Dividend- P/FCF- EPS past 5Y- ROI-20.00% 52W High-20.70% Beta-
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low162.82% ATR2.48
Employees364 Current Ratio6.20 Sales Q/Q-67.50% Oper. Margin-98.50% RSI (14)56.95 Volatility5.35% 4.71%
OptionableYes Debt/Eq0.49 EPS Q/Q-235.30% Profit Margin- Rel Volume1.87 Prev Close41.00
ShortableYes LT Debt/Eq0.49 EarningsAug 07 AMC Payout- Avg Volume722.29K Price41.00
Recom1.30 SMA208.16% SMA5019.42% SMA20053.66% Volume1,348,330 Change0.00%
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Citigroup Buy
Sep-23-15Initiated Lake Street Hold $25
Jul-29-15Initiated Citigroup Buy $37
Jul-20-15Upgrade Goldman Neutral → Buy
Dec-09-14Initiated Stifel Buy $39
Dec-09-14Initiated RBC Capital Mkts Outperform $38
Aug-17-17 09:26AM  Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment TheStreet.com
Aug-15-17 11:32PM  FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock GlobeNewswire -6.24%
Aug-14-17 04:26PM  FibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock GlobeNewswire +5.76%
Aug-12-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Aug-11-17 11:45PM  Edited Transcript of FGEN earnings conference call or presentation 7-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:03AM  IHS Markit Score Update: Drop in demand for ETFs holding FibroGen Inc is a negative sign for its shares Markit -5.84%
Aug-09-17 08:46AM  Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data Zacks -11.82%
08:43AM  Strength Seen in FibroGen (FGEN): Stock Soars 48.2% Zacks
Aug-08-17 04:20PM  Why Ralph Lauren, LendingClub, and FibroGen Jumped Today Motley Fool +48.20%
03:06PM  Why Did FibroGen (FGEN) Stock Hit All-Time High Today? Zacks
02:37PM  Why FibroGen Inc Skyrocketed Higher Today Motley Fool
11:07AM  Biotech FibroGen soars more than 50% on positive lung disease treatment study CNBC
10:55AM  Why Fibrogen Shares Are Exploding 24/7 Wall St.
10:54AM  FibroGen shares surge 49% on positive mid-stage trial for pulmonary fibrosis therapy MarketWatch
09:29AM  Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study TheStreet.com
Aug-07-17 11:00PM  FibroGen reports 2Q loss Associated Press
04:50PM  FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis GlobeNewswire
04:39PM  FibroGen Reports Second Quarter 2017 Financial Results GlobeNewswire
12:10PM  Investor Network: FibroGen, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 08:51AM  Should You Buy FibroGen (FGEN) Ahead of Earnings? Zacks
Jul-31-17 07:00PM  FibroGen to Report Second Quarter Financial Results on Monday, August 7, 2017 GlobeNewswire
Jun-21-17 10:10PM  FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer GlobeNewswire
Jun-13-17 07:00AM  About FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference GlobeNewswire
Jun-05-17 07:00AM  European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology GlobeNewswire
Jun-02-17 02:07PM  ETFs with exposure to FibroGen, Inc. : June 2, 2017 Capital Cube
08:41AM  FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 2, 2017 Capital Cube
May-24-17 09:01PM  Edited Transcript of FGEN earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-22-17 01:39PM  ETFs with exposure to FibroGen, Inc. : May 22, 2017 Capital Cube
May-19-17 09:47AM  FibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 Capital Cube
May-15-17 04:05PM  Akebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact TheStreet.com
May-10-17 09:25PM  Edited Transcript of FGEN earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-09-17 04:02PM  FibroGen Reports First Quarter 2017 Financial Results GlobeNewswire
03:00PM  Investor Network: FibroGen, Inc. to Host Earnings Call Accesswire
May-05-17 05:22PM  Mylan (MYL) Q1 Earnings: Will the Stock Pull a Surprise? Zacks
11:02AM  What's in the Cards for Repros (RPRX) this Earnings Season? Zacks
08:45AM  Should You Sell FibroGen, Inc (FGEN) Before Earnings? Zacks
May-04-17 05:32PM  Is Endo (ENDP) Poised for a Beat This Earnings Season? Zacks
05:21PM  Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings? Zacks
10:34AM  What's in the Cards for Allergan (AGN) this Earnings Season? Zacks
10:32AM  Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store? Zacks
10:29AM  Can Ligand (LGND) Spring a Surprise this Earnings Season? Zacks
May-03-17 04:50PM  What's in Store for Mallinckrodt (MNK) This Earnings Season? Zacks
04:36PM  What to Expect from Epizyme (EPZM) This Earnings Season? Zacks
04:34PM  What's in Store for Adverum (ADVM) in Q1 Earnings? Zacks
04:28PM  What's in the Cards for Inovio (INO) This Earnings Season? Zacks
03:36PM  Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards? Zacks
10:44AM  Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? Zacks
10:35AM  Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint? Zacks
07:00AM  FibroGen to Report First Quarter Financial Results on May 9, 2017 GlobeNewswire
May-02-17 06:40PM  What's in Store for Catalyst (CPRX) Stock in Q1 Earnings? Zacks
06:38PM  Will Intrexon (XON) Pull Off a Surprise in Q1 Earnings? Zacks
06:28PM  GW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect? Zacks
09:11AM  What's in the Cards for ACADIA (ACAD) this Earnings Season? Zacks
May-01-17 04:14PM  Radius Health (RDUS) Q1 Earnings: What's in Store? Zacks
04:06PM  What's in Store for Zoetis (ZTS) Stock This Earnings Season? Zacks
04:03PM  What to Expect from Endocyte (ECYT) Stock for Q1 Earnings? Zacks
Apr-28-17 06:19PM  Is Intercept (ICPT) Poised for a Beat This Earnings Season? Zacks
06:07PM  What to Expect from Keryx (KERX) Stock This Earnings Season? Zacks
Apr-27-17 12:03PM  What's in the Cards for Merrimack (MACK) in Q1 Earnings? Zacks
Apr-26-17 04:19PM  What to Expect from Prothena (PRTA) This Earnings Season? Zacks
10:59AM  Akebia Surges but is Still Undervalued, Making Takeover a Potential Remedy TheStreet.com
09:04AM  What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings? Zacks
Apr-25-17 07:00PM  Akebia expands anemia drug pact with Japanese firm, lifting shares American City Business Journals +5.46%
04:25PM  Akebia Expands Anemia Pill Partnership to Include Europe, China Rights TheStreet.com
Apr-06-17 12:59PM  Why FibroGen Inc Popped Higher Today Motley Fool +15.03%
10:38AM  Traders Are Focused on the Big-Caps TheStreet.com
07:00AM  FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock GlobeNewswire
Apr-04-17 08:23AM  FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : April 4, 2017 Capital Cube
Mar-31-17 07:09AM  FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:05AM  FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS GlobeNewswire
Mar-30-17 07:00AM  Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease GlobeNewswire
Mar-23-17 08:05AM  FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : March 23, 2017
Mar-07-17 01:04PM  FIBROGEN INC Financials
11:56AM  FibroGen, Inc. :FGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Capital Cube
Mar-02-17 04:40PM  FIBROGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement
03:04PM  Edited Transcript of FGEN earnings conference call or presentation 1-Mar-17 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-17 04:30PM  FibroGen Inc Earnings Call scheduled for 4:30 pm ET today
04:07PM  FIBROGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:02PM  FibroGen Reports Fiscal 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 FibroGen Inc Earnings Release - After Market Close
Feb-22-17 10:37PM  FibroGen to Report Fiscal 2016 Financial Results on March 1, 2017 GlobeNewswire
Feb-16-17 08:02AM  FIBROGEN INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Feb-03-17 11:06AM  FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy GlobeNewswire +5.27%
Jan-31-17 09:32AM  FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 31, 2017 Capital Cube
Jan-30-17 09:21AM  Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen -6.44%
08:25AM  Aurinia Pharmaceuticals (AUPH) Jumps: Stock Rises 5.6%
07:07AM  FIBROGEN INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  FibroGens Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China GlobeNewswire
Jan-23-17 08:01AM  FibroGen (FGEN) Shares March Higher, Can It Continue? -5.86%
Jan-20-17 05:06PM  Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium GlobeNewswire
Jan-17-17 09:40AM  Here Are Two Market Moving Biotech Catalysts To Watch This Week at Insider Monkey -7.25%
Jan-06-17 10:25AM  6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
Jan-05-17 12:56PM  Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc. at Motley Fool
Dec-30-16 10:45AM  Will 2017 Be a Make or Break Year for FibroGen?
Dec-23-16 09:26AM  FibroGen, Inc. Value Analysis (NASDAQ:FGEN) : December 23, 2016 +6.67%
Dec-22-16 07:26AM  FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : December 22, 2016
Dec-20-16 02:19PM  Why Akebia Therapeutics Inc Stock Zoomed Higher Today at Motley Fool
07:01AM  Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights
Dec-16-16 01:40PM  ETFs with exposure to FibroGen, Inc. : December 16, 2016
Dec-10-16 03:47PM  Is FibroGen Inc (FGEN) a Good Stock to Buy? at Insider Monkey
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cotroneo PatVP, Finance and CFOAug 08Option Exercise13.4195,0001,273,875258,366Aug 10 07:14 PM
Yu K PeonyChief Medical OfficerAug 08Option Exercise14.5820,000291,500236,507Aug 10 07:16 PM
Cotroneo PatVP, Finance and CFOAug 08Sale50.6195,0004,808,038163,366Aug 10 07:14 PM
Yu K PeonyChief Medical OfficerAug 08Sale50.5837,5001,896,861199,007Aug 10 07:16 PM
Cotroneo PatVP, Finance and CFOAug 02Option Exercise8.2220,746170,445184,112Aug 03 08:16 PM
Cotroneo PatVP, Finance and CFOAug 02Sale34.1320,746708,061163,366Aug 03 08:16 PM
Cotroneo PatVP, Finance and CFOAug 01Option Exercise3.367,60025,543170,966Aug 03 08:16 PM
Yu K PeonyChief Medical OfficerAug 01Option Exercise14.5810,000145,750226,507Aug 03 08:18 PM
Cotroneo PatVP, Finance and CFOAug 01Sale33.547,600254,904163,366Aug 03 08:16 PM
Yu K PeonyChief Medical OfficerAug 01Sale33.4810,000334,800216,507Aug 03 08:18 PM
Neff Thomas BChief Executive OfficerJul 25Option Exercise2.3518,90044,4153,330,780Jul 26 04:41 PM
Neff Thomas BChief Executive OfficerJul 25Sale35.1218,900663,7683,311,880Jul 26 04:41 PM
Neff Thomas BChief Executive OfficerJul 25Sale35.1141814,676135,038Jul 26 04:41 PM
Neff Thomas BChief Executive OfficerJul 24Option Exercise2.3518,90044,4153,330,780Jul 26 04:41 PM
Neff Thomas BChief Executive OfficerJul 24Sale35.0618,900662,6343,311,880Jul 26 04:41 PM
Neff Thomas BChief Executive OfficerJul 24Sale35.0941814,668135,456Jul 26 04:41 PM
Kurkijarvi KaleviDirectorJul 17Sale33.452,00066,90032,000Jul 18 04:26 PM
Yu K PeonyChief Medical OfficerJul 10Sale32.985,000164,900216,507Jul 11 07:38 PM
Neff Thomas BChief Executive OfficerJul 07Option Exercise2.3518,90044,4153,330,780Jul 07 06:50 PM
Neff Thomas BChief Executive OfficerJul 07Sale33.2218,900627,8583,311,880Jul 07 06:50 PM
Neff Thomas BChief Executive OfficerJul 07Sale33.2441813,894135,874Jul 07 06:50 PM
Cotroneo PatVP, Finance and CFOJul 06Option Exercise2.904,00011,600167,366Jul 07 04:33 PM
Neff Thomas BChief Executive OfficerJul 06Option Exercise2.3518,90044,4153,330,780Jul 07 06:50 PM
Cotroneo PatVP, Finance and CFOJul 06Sale34.004,000136,000163,366Jul 07 04:33 PM
Neff Thomas BChief Executive OfficerJul 06Sale33.5318,900633,7953,311,880Jul 07 06:50 PM
Neff Thomas BChief Executive OfficerJul 06Sale33.4941814,000136,292Jul 07 06:50 PM
Cotroneo PatVP, Finance and CFOJun 22Option Exercise2.903,0008,700166,366Jun 23 04:39 PM
Neff Thomas BChief Executive OfficerJun 22Option Exercise2.3518,90044,4153,330,780Jun 23 04:38 PM
Cotroneo PatVP, Finance and CFOJun 22Sale32.003,00096,000163,366Jun 23 04:39 PM
Neff Thomas BChief Executive OfficerJun 22Sale31.8818,900602,4763,311,880Jun 23 04:38 PM
Neff Thomas BChief Executive OfficerJun 22Sale32.0241813,384136,710Jun 23 04:38 PM
Neff Thomas BChief Executive OfficerJun 21Option Exercise2.3518,90044,4153,330,780Jun 23 04:38 PM
Neff Thomas BChief Executive OfficerJun 21Sale31.1518,900588,7353,311,880Jun 23 04:38 PM
Neff Thomas BChief Executive OfficerJun 21Sale31.2241813,050137,128Jun 23 04:38 PM
Cotroneo PatVP, Finance and CFOJun 19Option Exercise2.355,50012,925168,866Jun 21 06:00 PM
Cotroneo PatVP, Finance and CFOJun 19Sale30.005,500165,000163,366Jun 21 06:00 PM
Neff Thomas BChief Executive OfficerJun 16Option Exercise2.3518,90044,4153,330,780Jun 19 05:49 PM
Neff Thomas BChief Executive OfficerJun 16Sale29.5841812,364137,546Jun 19 05:49 PM
Neff Thomas BChief Executive OfficerJun 16Sale29.5418,900558,3063,311,880Jun 19 05:49 PM
Neff Thomas BChief Executive OfficerJun 15Option Exercise2.3511,68927,4693,330,780Jun 19 05:49 PM
Neff Thomas BChief Executive OfficerJun 15Sale29.2841812,239137,964Jun 19 05:49 PM
Neff Thomas BChief Executive OfficerJun 15Sale29.2518,900552,8253,311,880Jun 19 05:49 PM
Kurkijarvi KaleviDirectorJun 15Sale28.502,00057,00034,000Jun 19 05:50 PM
Yu K PeonyChief Medical OfficerJun 14Sale28.953,721107,723221,507Jun 16 04:49 PM
Tamura ToshinariDirectorJun 12Option Exercise9.0115,000135,15063,000Jun 13 07:32 PM
Cotroneo PatVP, Finance and CFOJun 12Sale28.752,89183,116163,366Jun 14 07:00 PM
Tamura ToshinariDirectorJun 12Sale28.5715,000428,55048,000Jun 13 07:32 PM
Tamura ToshinariDirectorJun 09Option Exercise3.9915,00059,85063,000Jun 13 07:32 PM
Tamura ToshinariDirectorJun 09Sale29.2015,000438,00048,000Jun 13 07:32 PM
KEARNS THOMAS F JRDirectorJun 06Option Exercise9.7818,000175,950156,564Jun 08 07:51 PM
KEARNS THOMAS F JRDirectorJun 06Sale28.7118,000516,780138,564Jun 08 07:51 PM
Neff Thomas BChief Executive OfficerMay 31Option Exercise2.3518,90044,4153,345,941Jun 01 07:23 PM
Neff Thomas BChief Executive OfficerMay 31Sale25.9718,900490,8333,327,041Jun 01 07:23 PM
Neff Thomas BChief Executive OfficerMay 31Sale26.0341810,881138,382Jun 01 07:23 PM
Cotroneo PatVP, Finance and CFOMay 30Option Exercise2.9010,00029,000169,326Jun 01 07:22 PM
Neff Thomas BChief Executive OfficerMay 30Option Exercise2.3518,90044,4153,345,941Jun 01 07:23 PM
Neff Thomas BChief Executive OfficerMay 30Sale26.4518,900499,8243,327,041Jun 01 07:23 PM
Neff Thomas BChief Executive OfficerMay 30Sale26.3041810,993138,800Jun 01 07:23 PM
Neff Thomas BChief Executive OfficerMay 16Option Exercise2.3518,90044,4153,345,941May 17 08:52 PM
Kurkijarvi KaleviDirectorMay 16Sale27.402,00054,80036,000May 17 09:06 PM
Neff Thomas BChief Executive OfficerMay 16Sale27.6741811,566139,218May 17 08:52 PM
Neff Thomas BChief Executive OfficerMay 16Sale27.6418,900522,3963,327,041May 17 08:52 PM
Neff Thomas BChief Executive OfficerMay 15Option Exercise2.3518,90044,4153,345,941May 17 08:52 PM
Neff Thomas BChief Executive OfficerMay 15Sale27.8141811,625139,636May 17 08:52 PM
Neff Thomas BChief Executive OfficerMay 15Sale27.7518,900524,4753,327,041May 17 08:52 PM
Yu K PeonyChief Medical OfficerMay 10Sale26.385,000131,890226,046May 12 06:22 PM
Neff Thomas BChief Executive OfficerApr 25Option Exercise3.1318,90059,1453,345,941Apr 26 07:31 PM
Cotroneo PatVP, Finance and CFOApr 25Option Exercise2.356,50015,275164,405Apr 27 08:44 PM
Yu K PeonyChief Medical OfficerApr 25Option Exercise14.585,00072,875236,046Apr 27 08:45 PM
Yu K PeonyChief Medical OfficerApr 25Sale28.005,000140,000231,046Apr 27 08:45 PM
Cotroneo PatVP, Finance and CFOApr 25Sale28.006,500182,000157,905Apr 27 08:44 PM
Neff Thomas BChief Executive OfficerApr 25Sale27.6741811,566140,054Apr 26 07:31 PM
Neff Thomas BChief Executive OfficerApr 25Sale27.4918,900519,5613,327,041Apr 26 07:31 PM
Neff Thomas BChief Executive OfficerApr 24Option Exercise4.0318,90076,0733,345,941Apr 26 07:31 PM
Neff Thomas BChief Executive OfficerApr 24Sale26.4541811,056140,472Apr 26 07:31 PM
Neff Thomas BChief Executive OfficerApr 24Sale26.3518,900498,0153,327,041Apr 26 07:31 PM
Kurkijarvi KaleviDirectorApr 17Sale25.252,00050,50038,000Apr 19 06:11 PM
Neff Thomas BChief Executive OfficerApr 13Option Exercise4.0318,90076,0733,345,941Apr 14 06:06 PM
Neff Thomas BChief Executive OfficerApr 13Sale24.9118,900470,7993,327,041Apr 14 06:06 PM
Neff Thomas BChief Executive OfficerApr 13Sale24.9541810,429140,890Apr 14 06:06 PM
Neff Thomas BChief Executive OfficerApr 12Option Exercise4.0318,90076,0733,345,941Apr 14 06:06 PM
Neff Thomas BChief Executive OfficerApr 12Sale24.6718,900466,1723,327,041Apr 14 06:06 PM
Neff Thomas BChief Executive OfficerApr 12Sale24.5741810,270141,308Apr 14 06:06 PM
Neff Thomas BChief Executive OfficerApr 04Option Exercise4.0318,90076,0733,345,941Apr 04 09:39 PM
Neff Thomas BChief Executive OfficerApr 04Sale23.804189,948141,726Apr 04 09:39 PM
Neff Thomas BChief Executive OfficerApr 04Sale23.8518,900450,7653,327,041Apr 04 09:39 PM
Neff Thomas BChief Executive OfficerApr 03Option Exercise4.0318,90076,0733,345,941Apr 04 09:39 PM
Neff Thomas BChief Executive OfficerApr 03Sale23.924189,999142,144Apr 04 09:39 PM
Neff Thomas BChief Executive OfficerApr 03Sale23.9918,900453,4113,327,041Apr 04 09:39 PM
Neff Thomas BChief Executive OfficerMar 21Option Exercise4.0318,90076,0733,345,941Mar 22 06:36 PM
Neff Thomas BChief Executive OfficerMar 21Sale23.584189,856142,562Mar 22 06:36 PM
Neff Thomas BChief Executive OfficerMar 21Sale23.8018,900449,8003,327,041Mar 22 06:36 PM
Neff Thomas BChief Executive OfficerMar 20Option Exercise4.0318,90076,0733,345,941Mar 22 06:36 PM
Neff Thomas BChief Executive OfficerMar 20Sale24.9241810,417142,980Mar 22 06:36 PM
Neff Thomas BChief Executive OfficerMar 20Sale24.8818,900470,2323,327,041Mar 22 06:36 PM
Neff Thomas BChief Executive OfficerMar 15Option Exercise4.0310,85843,7033,345,941Mar 16 07:29 PM
Neff Thomas BChief Executive OfficerMar 15Sale25.0719,318484,382143,398Mar 16 07:29 PM
Neff Thomas BChief Executive OfficerMar 14Option Exercise4.0310,85843,7033,353,983Mar 16 07:29 PM
Neff Thomas BChief Executive OfficerMar 14Sale25.0618,900473,6313,335,083Mar 16 07:29 PM
Neff Thomas BChief Executive OfficerMar 14Sale25.0241810,458143,816Mar 16 07:29 PM